KRAS and non-small cell lung carcinoma: Encouragingly, the inhibitors targeting KRAS G12C mutations such as sotorasib (AMG-510) and adagrasib (MRTX849) have been approved for clinical use by the FDA in recent years and have achieved certain response results in NSCLC [50, 51].